Peptide Library

Human study PLS-00161

Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.

Other design · Not reported participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.primary · Scientific reports · 2017-08-22 · PMID 28831179 · DOI

Design and participants

Design
Other design
Population
Patients with head and neck squamous cell carcinoma who provided paired normal and tumor tissue samples
Conditions
Head and neck squamous cell carcinoma
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Global proteomics identified TMSB4X as a new HNSCC biomarker. Its overexpression was linked to poorer overall and recurrence-free survival and to enhanced proliferation and metastasis. It may be a potential therapeutic target.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: The study measures endogenous tumor TMSB4X expression and does not administer thymosin beta-4 to any participant.
    • abstract only: Only the PubMed abstract is available in the record. Sample sizes, methods and funding are not described.
    • inappropriate population: The study measures endogenous protein expression in tumor tissue and gives no thymosin beta-4 to people, so it cannot inform the effects or safety of administering the compound.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 28831179, abstract (sentences 8-9) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 28831179, abstract (sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 28831179, abstract (sentence 2) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).